Prominently Increased of Mannose Binding Lectin (MBL) and Myeloperoxidase (MPO) Levels in Severe Valve Regurgitation and Heart Failure of Rheumatic Heart Disease by Putri, R. (Rachmania) et al.
THE JOURNAL OF TROPICAL LIFE SCIENCE                                                      OPEN     ACCESS Freely available online
VOL. 7, NO. 2, pp. 108 – 114, April 2017                          Submitted June 2016; Revised October 2016; Accepted February 2017
Prominently Increased of Mannose-Binding Lectin (MBL) and Myeloperoxidase (MPO) Levels in
Severe Valve Regurgitation and Heart Failure of Rheumatic Heart Disease 
Rachmania Putri 1,2 *, Renny Suwarniaty 2, 4, Loeki Enggar Fitri 1, Susanto Nugroho 2, 4, Mohammad Saifur Rahman 3, 5
1 Department of Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
2 Departments of Pediatrics, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
3 Departments of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University, Malang, Indonesia
4 Departments of Pediatrics, dr. Saiful Anwar Public Hospital, Malang, Indonesia
5 Departments of Cardiology and Vascular Medicine, dr. Saiful Anwar Public Hospital, Indonesia
ABSTRACT
Rheumatic heart disease (RHD) is mediated by an abnormal immunological response following a Streptococcus pyogenes infection
that induces a disturbance of oxidants and antioxidants balances. Mannose-binding lectin (MBL) binds to N-acetylglucosamine, a
molecule present on the Streptococcus cell wall and human heart valves. There is a disturbance of oxidant and antioxidant balance in
rheumatic disease. Myeloperoxidase (MPO) is a marker of oxidative stress and inflammation. This study was aimed to determine the
correlation of MBL and MPO levels and severity of valvular regurgitation and heart failure (HF) in RHD patients. A case-control
study was conduct using human peripheral blood samples from 32 children aged 6 to 14 years old. The subjects were divided into
two groups: 16 RHD patients included in the case group and 16 healthy children as a control group. The level of MBL and MPO was
investigated using ELISA method. There were significant differences on MBL and MPO level between patient and control group. The
level of MBL and MPO were significantly increased in RHD group, especially on severe valvular regurgitation. There was a strong
correlation between MBL and MPO levels and the severity of valvular regurgitation (r = 0.94 and r = 0.88). The least significant diff-
erence (LSD) analysis showed that significant difference occurs in the severe heart failure group. Our research revealed that the MBL
and MPO levels in pediatric RHD patients were significantly higher than in healthy children. The MBL and MPO levels were signifi -
cantly correlated with the severity of valvular regurgitation and heart failure.
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Rheumatic  heart  disease  is  a  sequela  of  acute
rheumatic fever (ARF) caused by group A streptococci
resulting in heart valve damage and can lead to heart
failure  in  severe  conditions.  Mannose-binding  lectin
(MBL)  binds  to  N-acetyl  glucosamine  (GIcNAC),  a
molecule found on the walls of Streptococcus and also
be found on the human heart valves [1].
Mannose-binding lectin is  an acute phase inflam-
matory proteins which act as a soluble receptor that
recognizes pathogens. Under normal conditions, MBL
can not bind its own network, but in a state of cellular
hypoxia, it can induce glycosylated cell surface causes
precipitation of MBL followed by activation of comple-
ment. Mannose-binding lectin binds to the surface of
the pathogen and has a major role in the innate im-
mune  response  through  the  ability  to  increase  op-
sonization  pathogens  and  activating  the  complement
cascade  via  the  lectin  pathway  [2].  Previous  study
showed  that  there  was  an  increase  of  MBL level  in
adult chronic RHD patients, which led to the specula-
tion that the MBL caused complement activation con-
tributing to the pathogenesis of RHD [3, 4]. However
there has been no study examining the correlation be-
tween MBL levels and the severity of valvular regurgi-
tation and heart failure in pediatric RHD. 
There  is  suspected  role of  oxidative stress  in the
pathophysiology  of  rheumatic  heart  valve  disease.
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However,  the  underlying  mechanisms  are  still  not
widely known. The balances between oxidant and an-
tioxidant systems are impaired in many inflammatory
diseases.  Increased oxidative stress  decreases  immune
system function and plays a role in the pathogenesis of
autoimmune disorders,  due to cell  apoptosis.  Conse-
quently, the oxidative stress is the result of severe in-
flammation and expected to contribute to the damage
of  heart  valve  disease  [5].  Previous  research  showed
that oxidant and antioxidant balance disorders lead to
the increase of oxidative stress in acute rheumatic fever
[6]. The level of oxidative stress is also increased in pa-
tients with severe mitral regurgitation and in the condi-
tion of heart failure that can occur as a complication of
acute rheumatic fever [7, 8].
Myeloperoxidase (MPO) is  a  marker  of  oxidative
stress  and  inflammation.  Recent  studies  showed  the
role of MPO in increasing the risk of various cardio-
vascular diseases [9, 10]. Myeloperoxidase is a leuko-
cyte-derived  enzyme  that  catalyzes  the  formation  of
ROS and consumes nitric oxide (NO) resulting in en-
dothelial  dysfunction [11]. In human, there is an in-
crease of systemic MPO in patients with chronic sys-
tolic  heart  failure  [7].  Enzymatically,  MPO,  together
with  hydrogen  peroxide  and  chloride,  produces
hypochlorous acid, an adamant oxidant. Myeloperoxi-
dase is an important contributor to oxygen-dependent
tissue damage in autoimmune and chronic inflamma-
tory diseases [12]. It is known that there were chronic
inflammation and autoimmune reaction in the case of
rheumatic fever [4]. Until now, there was no study that
examined  the  MPO level  in  pediatric  RHD patients
and the relationship of MPO level and the severity of
valvular  regurgitation  and  heart  failure  in  pediatric
RHD patients.
Design and study population
This case-control study was conducted at Paediatric
Cardiology Clinic dr.  Saiful  Anwar General  Hospital
(SAGH) Malang, Indonesia from 1st  June 2014 to 31st
September 2014. This study enrolled 32 children who
were  divided  into  two  groups,  RHD  patients,  and
healthy children as a control. The patient group con-
sisted of 16 RHD patients who came for their regular
follow up at Pediatric Cardiology Clinic SAGH, during
the period of  the  study (consecutive  sampling).  The
control group consisted of 16 healthy volunteer chil-
dren.
The inclusion criteria for patient group were chil-
dren aged 6 to 14 years old, who were diagnosed with
RHD, either with clinical heart failure or not, and had
taken therapy for less than 2 years depending on the
severity of the disease. Subjects who had acute inflam-
mation,  infection,  autoimmune  diseases,  hematologic
disorder,  and  other  cardiovascular  diseases  were  ex-
cluded from this study. 
Definition used in this study
The diagnosis of RHD was determined according to
Jones criteria which were modified by the world health
organization (WHO) in 2002-2003 for the diagnosis of
rheumatic fever (RF) and RHD.13 The valvular abnor-
malities  were  identified  by  echocardiography  per-
formed  by  cardiologist  consultant  pediatrician,  using
color jet flow area to determine the severity of valvular
regurgitation.  The  severity  of  valvular  abnormalities
were classified into mild, moderate, and severe valvular
regurgitation.  In this study,  the heart  failure severity
was classified using Ross score classifications when the
patient was admitted [14]. 
Ethical consideration
This study protocol was approved by the Research
Ethic Committee of the Faculty of Medicine, Brawijaya
University  dr.  Saiful  Anwar  Public  Hospital  No.
400/114/K.3/302/2014.  Informed  consents  were  ob-
tained from parents or legal guardians of all children. 
Blood collection
Peripheral blood samples were aseptically collected
from  the  patient  and  control  group  subjects  in  the
Pathology Clinic Laboratory of dr. Saiful Anwar Gen-
eral  Hospital.  The  MBL  from  plasma  concentration
was quantified using sandwich ELISA kit (Elabscience).
The MPO from plasma concentration was quantified
using  sandwich  ELISA kit  (BioLegend)  according  to
the instructions of the manufacturer. 
Statistical analysis
Data was entered and analyzed using SPSS statisti-
cal  package  version  21.  The  independent  t-test  was
used to analyze the difference of MBL and MPO levels
in the patient group compared to control group. One
way ANOVA was used to differentiate MBL and MPO
levels among mild, moderate, and severe valvular re-
gurgitation and also among mild, moderate, and severe
heart failure. For all tests, a p-value of less than 0.05
was significant with 95% confidence intervals.
The 16 children were suffering from RHD and 16 
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Table 1. Characteristics of the subjects
Characteristic of subject Patient (n=16) Control (n=16)
Sex:
Male 7 (7/16) 7 (7/16)
Female 9 (9/16) 9 (9/16)
Age (Year) 10.84 ± 2.5 10.44 ± 1.15
Most populated area:
Yes 11 (11/16) 6 (6/16)
No 5 (5/16) 10 (10/16)
Nutritional status:
Undernutrition 10 (10/16)* 3 (3/16)
Good 4 (4/16) 10 (10/16)*
Overweight 2 (2/16) 3 (3/16)
Valve regurgitation:
Mild 6 (6/16) -
Moderate 5 (5/16) -
Severe 5 (5/16) -
Heart Failure:
Yes 12 (12/16) -
No 4 (4/16) -
Duration of treatment:
< 12 months 8 (8/16) -
12 months≥ 8 (8/16) -
Note: * In this group of patients showed the majority nutri-
tional  status  was  malnutrition,  whereas  the  control
group showed the majority nutritional status was good
nutrition.
healthy children as a control group. The mean age in
RHD patients and control group were 10.84 ± 2.5 years
old and 10.44 ± 1.15 years old, respectively. In the pa-
tient group, 7 of 16 subjects were male, and 10 subjects
were with undernourished status. In control group, 7
of 16 subjects were male, and 10 subjects were with
good nutritional status. From the RHD patients, 6 pa-
tients had mild valvular regurgitation, 5 patients had
moderate valvular regurgitation, and the other 5 had
severe  valvular  regurgitation.  There  were 12 patients
suffered from heart failure. Therapy was administered
in various time from 2 months to 2 years to each sub-
ject (Table 1). 
The mean of plasma MBL level  in the RHD pa-
tients was 2711 ± 14 ng/mL, higher than the control
group with mean MBL level of 906 ± 20 ng/mL (Figure
1). The average of plasma MPO level in RHD patients
was 126.13 ± 24 ng/mL, higher than the control group,
91.55 ± 7 ng/mL (Figure 2). Statistical analysis using
independent sample t test showed a significant differ
Figure 1. Comparison of MBL levels between patient and con-
trol group. The MBL levels of patient group as signif-
icantly higher (p = 0.00) than control group
Figure 2. Comparison of MPO levels between patient and con-
trol group. The MPO levels of patient group is signi-
ficantly higher (p = 0.00) than control group
ence in both MBL and MPO levels in RHD patients
compared to the control group. 
The  mean level  of  MBL and  MPO among mild,
moderate,  and  severe  valvular  regurgitation  patients
analyzed using one-way ANOVA showed a significant
difference. There was a very strong correlation between
MBL level and severity of valvular regurgitation (p =
0.00, r = 0.94) and a strong correlation between MPO
level and severity of valvular regurgitation (p = 0.00, r
=  0.86).  The  LSD analysis  comparing  the  MBL and
MPO levels among mild, moderate, and severe valvular
regurgitation showed that the differences occurred in
severe valvular regurgitation patients (Figure 3 dan 4).
The test results comparing the mean levels of both
MBL and MPO in RHD patients between patients with
and without heart failure using independent sample t-
test showed no significant difference with p = 0.07 and
p = 0.11. The mean level of MBL and MPO among
mild, moderate, and severe  heart failure  patients  ana-
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Figure 3. Comparison  of  MBL levels  among mild,  moderate,
and severe valve regurgitation. The LSD analysis to
compare MBL levels between mild to moderate valve
regurgitation (p = 0.00), moderate to severe valve re-
gurgitation (p = 0.03), and mild to severe valve regur-
gitation (p = 0.00)
Figure 4. Comparison of MPO levels  among mild,  moderate,
and severe valve regurgitation. The LSD analysis to
compare MPO levels between mild to moderate valve
regurgitation (p = 0.14), moderate to severe valve re-
gurgitation (p = 0.02), and mild to severe valve regur-
gitation (p = 0.00)
lyzed using one-way ANOVA showed a significant dif-
ference (p = 0.00). The LSD analysis to compare the
MBL and MPO levels among mild, moderate, and se-
vere heart failure was indicated in Figure 5 dan Figure
6.
The mean age of children in RHD patients was 10
years and 8 months. The incidence of ARF and RHD is
often found in children aged 6-15 years old. Based on
epidemiological studies, ARF/RHD are affected by low
socioeconomic  and  environmental  factors  associated
with the densely populated area, poor ventilation, and
inadequate nutrition [15]. In this study, the majority of
patients had poor nutritional status (10 of 16 children).
Figure 5. Comparison  of  MBL levels  among mild,  moderate,
and severe heart failure. The LSD analysis to compare
MBL levels between mild to moderate heart failure (p
= 0.84), moderate to severe heart failure (p = 0.04),
and mild to severe heart failure (p = 0.03)
Figure 6.  Comparison of MPO levels  among mild,  moderate,
and severe heart failure. The LSD analysis to compare
MPO levels between mild to moderate heart failure (p
= 0.65), moderate to severe heart failure (p = 0.01),
and mild to severe heart failure (p = 0.00).
The most commonly found valve lesion in RHD is mi-
tral  regurgitation.  In severe condition,  it  can lead to
heart failure [7]. Study by Kironget et al. (2014) inves-
tigating the characteristics of echocardiography in 84
children with RHD showed that most patients had se-
vere valvular abnormalities [16]. In this study, from 16
patients  with  RHD,  6  patients  suffered  from  mild
valvular regurgitation, 5 people suffered from moderate
valvular regurgitation, and 5 others suffered from se-
vere  valvular  regurgitation.  The  12  patients  suffered
from heart failure.
It is known that MBL binds to N-acetyl-β-D-glu-
cosamine tightly in the streptococcal cell wall and sub-
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sequently  lead  to the deposition of  complement  and
opsonization [17].  Mannose-binding lectin concentra-
tion in healthy Caucasians is approximately 800–1000
µg/L [3]. This study found that the mean level of MBL
was higher in children with RHD compared to healthy
children, 1211 ± 14 ng/mL vs 906.6 ± 7 ng/mL. Some
previous studies also showed increased levels of MBL
in RHD [3, 4, 18].
A study by Schafranski et  al.  (2004) showed that
there was a significant increase of MBL level in adult
RHD patients  compared  to  the  control  group.  This
study suggested that high level  of  MBL might  cause
undesirable  complement  activation  in  RHD  patients
and contributed to the pathogenesis of rheumatic car-
diomyopathy. The high level of MBL in chronic RHD
patients reinforces the presence of chronic inflamma-
tion activity contributing to valvular damage via com-
plement  activation  in  RHD patients  [3].  Subsequent
studies confirmed that high MBL level (> 2.80 ng/mL)
increased  the  risk  of  chronic  RHD (OR 2.91)  com-
pared to healthy control [4]. 
The high serum MBL level has been associated with
persistent  inflammation  and  tissue  damage.  In  addi-
tion, MBL can act as immunomodulatory molecules in-
ducing higher secretion of cytokines in the inflamma-
tory process. The complement activation occurs both in
acute and chronic cardiac injury.3,18 A prospective co-
hort study in 182 patients with chronic heart  failure
showed that complement activation was strongly corre-
lated  with  chronic  heart  failure  outcome.  Especially,
the high level of activated C3, C3a could be used as a
predictor of heart failure severity, and also associated
with  hospitalization  and  mortality  [19].  This  study
found that the increased level of MBL was parallel with
the severity of valvular regurgitation and heart failure
RHD patients. Chronic inflammatory disease induces
endothelial dysfunction, and it is known that heart fail-
ure is correlated with the severity of valvular damage in
RHD [20].
Myeloperoxidase  is  an  enzyme  released  by  neu-
trophils  which  stimulate  and  catalyzes  reactive  oxi-
dants, free radicals and nitric oxide formation, which
will  cause  tissue  damage.  Myeloperoxidase  has  been
widely used as a marker of oxidative stress in various
cardiovascular and autoimmune diseases [6, 21]. This
study was the first study using MPO biomarker in as-
sessing oxidative status in pediatric RHD patients The
results of this study showed that there was a significant
increase of MPO level in RHD patients compared to
the control group, 126.13 ± 24 ng/mL vs. 7.26±91.55
ng/mL.
Rheumatic  fever  has  the characteristics  of  an au-
toimmune disease triggered by streptococcal antigenic
cross-reactivity. A study investigating blood plasma of
38 patients aged 3-15 years old with chronic RHD and
ARF showed a high level of oxidative stress markers in
these  patients  [22].  There  was  a  study  that  demon-
strated that high oxidant protein products in chronic
RHD patients confirmed that there was a chronic in-
flammatory activity in RHD patients. Increased oxida-
tive stress is expected to play a role in the pathogenesis
of autoimmune disease due to its contribution to in-
flammation and cell apoptosis. As a consequence, the
oxidative stress, as a result of severe inflammation, is
predicted to have a major role in valvular damage in
RHD [6, 23].
A study by Tang et al.  (2006) showed that there
was a correlation between elevated MPO level and de-
gree of heart failure [8]. Increased MPO is associated
with endothelial dysfunction, which is the pathophysi-
ological process in heart  failure patients and is often
associated  with  a  worse  prognosis  [24].  Our  study
found that elevated MPO level  was parallel  with the
degree  of  valvular  regurgitation  and  heart  failure  in
RHD patients.
Rheumatic valve lesion is a chronic inflammatory
process, T cell infiltration to the valves plays a role in
the incidence of heart valve regurgitation and stenosis.
Mannose-binding lectin has an important role in the
inflammatory reaction through the activation of com-
plement.  Further,  complement activation may induce
some inflammatory effects,  such as the expression of
adhesion molecules, chemotaxis and leukocytes activa-
tion, the release of ROS, as well as the secretion of cy-
tokines  and chemokines  [25].  There are  various  evi-
dence showing the pro-inflammatory role of MBL in
tissue damage and severity of other inflammatory dis-
eases, particularly in cardiovascular disease [4, 5].
The balance between oxidants and antioxidants is
impaired in various inflammatory diseases. As a conse-
quence, the oxidative stress generated by the severe in-
flammation contributes to valve damage [5]. A study
by Chen et al.  (2012) showed that the increased in-
flammation was significantly correlated to the increase
of oxidative stress. Under stressful conditions such as
inflammatory  processes  mediated  by  oxidative  stress,
the cell surface undergo glycosylation and thus can be
targeted in MBL/ficolin binding. This in turn will lead
to pathological complement activation, and inflamma-
tion [26]. In vitro studies showed that oxidative stress
caused  formation  of  MBL  ligand  activating  comple-
ment in the endothelial cells [2].
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In  conclusion,  the  present  work  demonstrated  a
significant increase in MBL and MPO levels in RHD
patients.  The increases  in MBL and MPO levels  are
correlated with the severity of valvular regurgitation in
RHD patients  and  heart  failure,  especially  in  severe
condition.  This  result  supports  the  theory  of
inflammation and oxidative stress in RHD, providing a
new biomarker candidate that can predict the presence
of severe valvular regurgitation and worsening of heart
failure in RHD.
We would like to thank the Department of Child
Health,  Faculty  of  Medicine,  University  of
Brawijaya/dr.  Saiful  Anwar  Public  Hospital,  Malang,
Indonesia for providing the grant  to accomplish this
research.
1. Nayar  S,  Nayar  PG,  Cherian  KM  (2006)  Heart  valve
structure:  a predisposing factor  for rheumatic  heart  dis-
ease. Heart 92 (8): 1151–1152.
2. Collard CD, Vakeva A, Morrissey MA et al. (2000) Com-
plement activation after oxidative stress: role of the lectin
complement pathway. The American Journal of Pathology
156 (5): 1549–1556. doi: 10.1016/S0002-9440(10)65026-2.
3. Schafranski M, Stier A, Reason IJ (2004) Signiﬁcantly in-
creased  levels  of  mannose-binding  lectin  (MBL)  in
rheumatic  heart  disease:  a  beneﬁcial  role  for  MBL deﬁ-
ciency. Clinical Experimental Immunology 138 (3): 521–
525. doi: 10.1111/j.1365-2249.2004.02645.x.
4. Schafranski  MD,  Pereira  Ferrari  L,  Scherner  D  et  al.
(2008) High-producing MBL2 genotypes increase the risk
of acute and chronic carditis in patients  with history of
rheumatic fever.  Molecular Immunology 45 (14):  3827–
3831.
5. Karatas  Z,  Baysal  T,  Sap  F  et  al.  (2013)  The  role  of
tenascin-C and oxidative stress in rheumatic and congeni-
tal heart valve diseases: an observational study. The Ana-
tolian Journal of Cardiology 13 (4): 350-356.
6. Uner A, Sal E, Dogan M et al. (2010) Investigation of oxi-
dant and antioxidant pathway changes in acute rheumatic
fever. Acta Cardiology 65 (1): 53-57.
7. Chen  MC, Chang JP,  Liu  WH et  al.  (2009)  Increased
serum oxidative stress in patients with severe mitral regur-
gitation: a new finding and potential mechanism for atrial
enlargement. Clinical Biochemistry 42 (10–11): 943–948.
8. Tang  W,  Brennan  ML,  Philip  P  et  al.  (2006)  Plasma
myeloperoxidase levels in patients with chronic heart fail-
ure. The American Journal of Cardiology 98 (6): 796 –
799.
9. Morrow  DA,  Sabatine  MS,  Brennan  ML  et  al.  (2008)
Concurrent  evaluation  of  novel  cardiac  biomarkers  in
acute  coronary  syndrome:  myeloperoxidase  and  soluble
CD40 ligand and the risk of recurrent ischaemic events in
TACTICS-TIMI  18.  European  Heart  Journal  29  (9):
1096–1102. doi: 10.1093/eurheartj/ehn071.
10. Heslop CL, Frohlich JJ, Hill  JS (2010) Myeloperoxidase
and  C-reactive  protein  have  combined  utility  for  long-
term prediction of cardiovascular mortality after coronary
angiography. Journal of the American College of Cardiol-
ogy 55 (11): 1102–1109. doi: 10.1016/j.jacc.2009.11.050.
11. Vita  JA,  Brennan  ML,  Gokce  N  et  al.  (2004)  Serum
myeloperoxidase levels independently predict endothelial
dysfunction in humans. Circulation 110 (9): 1134–1139.
12. Odobasic D, Yang Y, Muljadi RC et al. (2014) Endoge-
nous myeloperoxidase is a mediator of joint inflammation
and damage in experimental artritis. Artritis and Rheuma-
tology 66: 907-914.
13. WHO Technical  Report  Series  (2004)  Rheumatic  fever
and rheumatic heart disease. World Health Organization,
Report No 923, Geneva,1–12.
14. Ross RD (2012) The Ross classification for heart failure in
children after 25 years: a review and an age-stratified revi-
sion.  Pediatric  Cardiology  33  (8):  1295-1300.
doi:10.1007/s00246-012-0306-8.
15. Madiyono B, Sukardi R, Kuswiyanto RB (2009) Demam
reumatik dan penyakit jantung reumatik pada anak. In:
Management of Pediatric Heart Diseases for Practitioners.
From Early Detection to Intervention. Departemen Ilmu
Kesehatan Anak FKUI-RSCM, 95-114.
16. Kironget AC (2014) Clinical profile of paediatric patients
with rheumatic disease at Moi Teaching and Referral Hos-
pital (MTRH) Kenya. Journal of Biology, Agriculture and
Healthcare 2 (4): 2224-3208.
17. Beltrame MH, Catarino SJ, Goeldner I et al. (2015) The
lectin pathway of complement and rheumatic heart dis-
ease. Frontiers in Pediatrics 2: 1–14. doi: 10.3389/fped.
2014.00148.
18. Pradhan V, Surve P, Ghosh K (2010) Mannose binding
lectin (MBL) in autoimmunity and its role in systemic lu-
pus  erythematosus  (SLE).  Journal  of  the Association of
Physicians of India 58: 688-690.  
19. Gombos T, Forhecz Z, Pozsonyi Z et al. (2012) Comple-
ment anaphylatoxin C3a as a novel independent prognos-
tic marker in heart failure. Clinical Research in Cardiol-
ogy 101 (8): 607–615. doi: 10.1007/s00392-012-0432-6.
20. Steyers CM, Miller FJ (2014) Endothelial dysfunction in
chronic  inflammatory  diseases.  International  Journal  of
Molecular Sciences 15 (7): 11324-11349. doi: 10.3390/ijms
150711324.





Prominently Increased of Mannose-Binding Lectin (MBL) and Myeloperoxidase (MPO)  
21. Stamp LK, Khalilova I, Tarr JM et al. (2012) Myeloperoxi-
dase and oxidative stress in rheumatoid artritis. Rheuma-
tology 193: 1-8.
22. Shanidze E, Zhvania M (2005) Activity of lipid peroxida-
tion processes and the condition of antioxidative defense
system in children with rheumatic fever. Georgian Medi-
cal News 127: 38-40.
23. Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Rea-
son IJ (2006) Further evidence of inflammation in chronic
rheumatic valve disease (CRVD): high levels of advanced
oxidation protein products (AOPP) and high sensitive C-
reactive protein (hs-CRP). International Journal of Cardi-
ology 109: 275-276.
24. Katz SD, Hryniewicz K, Hriljac I et al. (2005) Vascular
endothelial dysfunction and mortality risk in patients with
chronic heart failure. Circulation 111: 310-314.
25. Guilherme  L,  Cury  P,  Demarchi  LM  et  al.  (2004)
Rheumatic heart disease: proinflammatory cytokines play
a role in the progression and maintenance of valvular le-
sions.  The  American  Journal  of  Pathology  165:  1583–
1591.
26. Chen SJ, Yen CH, Huang YC et al. (2012) Relationships
between  inflammation,  adiponectin,  and oxidative  stress
in  metabolic  syndrome.  PLoS  ONE  7  (9):  e45693.
doi:10.1371/journal.pone.0045693.
27. Grayburn PA (2008) How to measure severity of mitral
regurgitation. Heart 94: 376-383.
JTLS | J. Trop. Life. Science 109 Volume 7 | Number 2 | April| 201714
